Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
The observations are procedural in nature
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
The objective of launching these products at AAHAR is to create awareness on the consumption of protein based products
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
